Chen Hongming 4
4 · Kala Pharmaceuticals, Inc. · Filed Mar 3, 2021
Insider Transaction Report
Form 4
Chen Hongming
Chief Scientific Officer10% Owner
Transactions
- Exercise/Conversion
Common Stock
2021-03-01$2.30/sh+9,500$21,850→ 243,015 total - Exercise/Conversion
Stock Option (right to buy
2021-03-01−9,500→ 53,736 totalExercise: $2.30Exp: 2024-10-02→ Common Stock (9,500 underlying)
Footnotes (2)
- [F1]Includes 99,666 unvested RSUs.
- [F2]The option was fully vested.